GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NKGen Biotech Inc (NAS:NKGN) » Definitions » Short-Term Debt

NKGen Biotech (NKGen Biotech) Short-Term Debt : $11.57 Mil (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is NKGen Biotech Short-Term Debt?

NKGen Biotech's Short-Term Debt for the quarter that ended in Mar. 2024 was $11.57 Mil.

NKGen Biotech's quarterly Short-Term Debt increased from Sep. 2023 ($5.23 Mil) to Dec. 2023 ($9.99 Mil) and increased from Dec. 2023 ($9.99 Mil) to Mar. 2024 ($11.57 Mil).

NKGen Biotech's annual Short-Term Debt declined from Dec. 2021 ($51.15 Mil) to Dec. 2022 ($11.66 Mil) and declined from Dec. 2022 ($11.66 Mil) to Dec. 2023 ($9.99 Mil).


NKGen Biotech Short-Term Debt Historical Data

The historical data trend for NKGen Biotech's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NKGen Biotech Short-Term Debt Chart

NKGen Biotech Annual Data
Trend Dec21 Dec22 Dec23
Short-Term Debt
51.15 11.66 9.99

NKGen Biotech Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Short-Term Debt Get a 7-Day Free Trial 11.66 - 5.23 9.99 11.57

NKGen Biotech Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


NKGen Biotech Short-Term Debt Related Terms

Thank you for viewing the detailed overview of NKGen Biotech's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


NKGen Biotech (NKGen Biotech) Business Description

Traded in Other Exchanges
N/A
Address
19700 Fairchild Road, Suite No. 300, Irvine, CA, USA, 92612
NKGen Biotech Inc is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer cell therapies utilizing our proprietary SNK (super-activated) platform.